In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

References

• Ah YM, Kim YM, Kim MJ, et al. (2008). Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev 40:511–37
   PubMed Web of Science ®Google Scholar
• Annaert P, Ye ZW, Stieger B, Augustijns P. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163–76
   PubMed Web of Science ®Google Scholar
• Barrail-Tran A, Mentre F, Cosson C, et al. (2010). Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother 54:614–19
   PubMed Web of Science ®Google Scholar
• Briz O, Serrano MA, Macias RI, et al. (2003). Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371:897–905
   PubMed Web of Science ®Google Scholar
• Campbell SD, De Morais SM, Xu JJ. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179–87
   PubMed Web of Science ®Google Scholar
• Choe PG, Park WB, Song JS, et al. (2010). Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. J Korean Med Sci 25:1427–30
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Leier I, et al. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–30
   PubMed Web of Science ®Google Scholar
• Di Stefano AF, Rusca A, Loprete L, et al. (2011). Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers. Antimicrob Agents Chemother 55:2122–8
   PubMed Web of Science ®Google Scholar
• Erdil A, Kadayifci A, Ates Y, et al. (2001). Rifampicin test in the diagnosis of Gilbert’s syndrome. Int J Clin Pract 55:81–3
   PubMed Web of Science ®Google Scholar
• Ertörer ME, Paydaş S, Saǧliker Y. (1997). Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy. Nephron 76:368
   PubMed Web of Science ®Google Scholar
• Fahrmayr C, Fromm MF, Konig J. (2010). Hepatic OATP and OCT uptake transporters: their role for drug--drug interactions and pharmacogenetic aspects. Drug Metab Rev 42:380–401
   PubMed Web of Science ®Google Scholar
• Gentile S, Porcellini M, Leo C, Foglia F. (1979). Influence of phenobarbital on hyperbilirubinemia caused by nicotinic acid and rifamycin–SV in healthy subjects. Boll Soc Ital Biol Sper 55:2184–9
   PubMedGoogle Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• He YJ, Zhang W, Tu JH, et al. (2008). Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 36:1453–6
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Gelder T, van Schaik RH, et al. (2004). Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76:545–56
   PubMed Web of Science ®Google Scholar
• Holladay JW, Dewey MJ, Michniak BB, et al. (2001). Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 29:299–303
   PubMed Web of Science ®Google Scholar
• Houin G, Beucler A, Richelet S, et al. (1983). Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther Drug Monit 5:67–72
   PubMed Web of Science ®Google Scholar
• Johnson AD, Kavousi M, Smith AV, et al. (2009). Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 18:2700–10
   PubMed Web of Science ®Google Scholar
• Kamisako T, Kobayashi Y, Takeuchi K, et al. (2000). Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 35:659–64
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, Huitema AD, Sankatsing SU, et al. (2005). Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 60:276–86
   PubMed Web of Science ®Google Scholar
• Kearns CM, Gianni L, Egorin MJ. (1995). Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16–23
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Waring JF, Morfitt DC, et al. (2006). Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 50:762–4
   PubMed Web of Science ®Google Scholar
• Keppler D, Konig J. (2000). Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis 20:265–72
   PubMed Web of Science ®Google Scholar
• Lankisch TO, Behrens G, Ehmer U, et al. (2009). Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy–an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol 50:1010–18
   PubMed Web of Science ®Google Scholar
• Lin Z, Fontaine J, Watchko JF. (2008). Coexpression of gene polymorphisms involved in bilirubin production and metabolism. Pediatrics 122:e156–62
   Web of Science ®Google Scholar
• Loos U, Musch E, Jensen JC, et al. (1985). Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205–11
   PubMedGoogle Scholar
• Lu JF, Blaschke TF, Flexner C, et al. (2002). Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metab Dispos 30:1455–61
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Schaefer O, Kawakami H, et al. (2011). Simultaneous absolute protein quantification of transporters, cytochrome P450s and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83–92
   PubMed Web of Science ®Google Scholar
• Okusanya O, Forrest A, Difrancesco R, et al. (2007). Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother 51:1822–6
   PubMed Web of Science ®Google Scholar
• PDR. (2012). Physicians’ Desk Reference, 2012 Edition, PDR Network
   Google Scholar
• Rafiq S, Iqbal T, Jamil A, Khan FH. (2010). Pharmacokinetic studies of rifampicin in healthy volunteers and tuberculosis patients. Int J Agric Biol 12:391--5
   Web of Science ®Google Scholar
• Rotger M, Taffe P, Bleiber G, et al. (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381–6
   PubMed Web of Science ®Google Scholar
• Sadler BM, Hanson CD, Chittick GE, et al. (1999). Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 43:1686–92
   PubMed Web of Science ®Google Scholar
• Sanna S, Busonero F, Maschio A, et al. (2009). Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 18:2711–18
   PubMed Web of Science ®Google Scholar
• Satija P, Parikh F, Aggarwal V, et al. (2002). Indirect hyperbilirubinemia with indinavir. J Assoc Physicians India 50:1316–17
   PubMedGoogle Scholar
• Smith NF, Marsh S, Scott-Horton TJ, et al. (2007). Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81:76–82
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Antinori A, et al. (2009). Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 37:244–9
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Stranecky V, Hartmannova H, et al. (2012). Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519–28
   PubMed Web of Science ®Google Scholar
• Vella S, Floridia M. (1998). Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 34:189–201
   PubMed Web of Science ®Google Scholar
• Wang P, Kim RB, Chowdhury JR, Wolkoff AW. (2003). The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem 278:20695–9
   PubMed Web of Science ®Google Scholar
• Watchko JF, Lin Z, Clark RH, et al. (2009). Complex multifactorial nature of significant hyperbilirubinemia in neonates. Pediatrics 124:e868–77
   PubMed Web of Science ®Google Scholar
• Zhang D, Chando TJ, Everett DW, et al. (2005). In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729–39
   PubMed Web of Science ®Google Scholar
• Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671–6
   PubMed Web of Science ®Google Scholar